Sylics

Acquired by InnoSer in 2023, Sylics’ preclinical neuroscience platform has been fully integrated into an expanded in vitro to in vivo neurology pipeline. We continue to develop and employ mouse models and behavioral tests that evaluate compound effects on neurological and psychiatric diseases. Now part of the InnoSer Group, Sylics remains a research-intensive company that develops research solutions in preclinical neuroscience. The InnoSer group runs preclinical neuroscience studies for national and international biotech, food & pharma partners. These studies focus on assessing the effect of novel therapeutic strategies to treat CNS and PNS disorders and diseases. We offer complimentary data analysis services to customers worldwide, using a proprietary cloud-based data analysis platform AHCODA™. This automated screening platform increases efficiency and sensitivity to detect behavioral deficits in mouse models.